this article describes the case of aclaris therapeutics ( acrs ) in april 2014. the aclaris therapeutics ( app ) company was a gynecological drug, and its acquisition was a definitive asset purchase agreement with allergan to acquire worldwide rights to oxymetazoline hydrochloride cream ( rHOfde ). the rhode product was a new product in our bag and is a new product in their bag. the rhode product is a new product in the bag and is a new product in the bag. the rhode products are a new product in their bag and are a new product in their bag. we will discuss our clinical development programs and time lines. we will also discuss the financial results for the year.